Home > Healthcare > Biotechnology > Biopharma > Polyclonal Antibodies Market

Polyclonal Antibodies Market Share

Report ID: GMI7456
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

Polyclonal Antibodies Market Share

The polyclonal antibodies industry is characterized by the presence of leading key players such as Thermo Fisher Scientific, Abcam plc, and Bio-Rad Laboratories. These companies engage in strategic initiatives, including product launches, collaborations, and acquisitions, to strengthen their market positions.

Prominent market players operating in the industry is as mentioned below:

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Merck Group (Merck KGaA)
Abcam plc
Bio-Rad Laboratories, Inc.
GenScript Biotech Corporation
Cell Signaling Technology, Inc.
Rockland Immunochemicals Inc.
BioLegend, Inc.
Santa Cruz Biotechnology, Inc.
Antibodies Inc.
Emergent

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for polyclonal antibodies was USD 1.4 billion in 2022 and is expected to reach USD 2.5 billion by 2032 due to the rising incidence of chronic diseases such as cancer, autoimmune conditions, and infectious diseases worldwide.

The secondary antibodies product segment held 66.4% industry share in 2022 and is expected to register appreciable CAGR from 2023-2032 due to their prominent role in signal amplification during detection methods like ELISA, western blotting and immunohistochemistry.

North America held 38.3% share of the industry in 2022 due to the presence of advanced healthcare infrastructure, substantial research & development activities, and robust biotechnology industry in the region.

F. Hoffmann-La Roche Ltd., Merck Group (Merck KGaA), Abcam plc, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., and BioLegend, Inc. are some of the major polyclonal antibodies companies worldwide.